StockNews.com Lowers Dynavax Technologies (NASDAQ:DVAX) to Hold

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a report issued on Wednesday.

Several other equities analysts also recently weighed in on DVAX. William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 23rd. The Goldman Sachs Group began coverage on Dynavax Technologies in a research report on Thursday, February 1st. They set a "neutral" rating and a $20.00 target price on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Dynavax Technologies presently has an average rating of "Moderate Buy" and an average target price of $25.00.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX traded down $0.06 on Wednesday, hitting $11.43. The company had a trading volume of 2,549,852 shares, compared to its average volume of 1,944,944. The company has a current ratio of 13.81, a quick ratio of 12.96 and a debt-to-equity ratio of 0.41. Dynavax Technologies has a 52-week low of $10.06 and a 52-week high of $15.15. The business has a 50 day moving average of $12.41 and a 200 day moving average of $13.35. The company has a market cap of $1.50 billion, a PE ratio of -190.47 and a beta of 1.26.

Insider Transactions at Dynavax Technologies

In other news, CAO Justin Burgess sold 20,526 shares of the firm's stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $12.78, for a total value of $262,322.28. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 9.31% of the company's stock.

Hedge Funds Weigh In On Dynavax Technologies

A number of large investors have recently modified their holdings of the company. American Century Companies Inc. grew its stake in shares of Dynavax Technologies by 4.7% in the first quarter. American Century Companies Inc. now owns 86,892 shares of the biopharmaceutical company's stock valued at $942,000 after buying an additional 3,902 shares in the last quarter. HighTower Advisors LLC acquired a new stake in shares of Dynavax Technologies in the first quarter valued at about $159,000. MetLife Investment Management LLC grew its stake in shares of Dynavax Technologies by 57.4% in the first quarter. MetLife Investment Management LLC now owns 57,543 shares of the biopharmaceutical company's stock valued at $624,000 after buying an additional 20,984 shares in the last quarter. Allianz Asset Management GmbH grew its stake in shares of Dynavax Technologies by 16.8% in the first quarter. Allianz Asset Management GmbH now owns 59,070 shares of the biopharmaceutical company's stock valued at $640,000 after buying an additional 8,500 shares in the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of Dynavax Technologies by 25.6% in the first quarter. Mackenzie Financial Corp now owns 16,190 shares of the biopharmaceutical company's stock valued at $175,000 after buying an additional 3,300 shares in the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.